

PATIENT NAME:
 MR #:
 DATE OF SERVICE:

SHORT DESC	CODE	CHOICE
DIAGNOSIS LUNG CANCER (Accepted Codes= 162.2-162.9)		
2 = MAIN BRONCHUS 3 =UPPER LOBE 4= MIDDLE LOBE 5= LOWER LOBE 8= OTHER PARTS OF THE LUNG 9= UNSPECIFIED		
ESTABLISHED PATIENT, OFFICE VISIT, PROBLEM FOCUSED	99212	
ESTABLISHED PATIENT, EXPANDED PROBLEM FOCUSED	99213	
ESTABLISHED PATIENT, DETAILED	99214	
ESTABLISHED PATIENT. COMPREHENSIVE	99215	
FOCUS OF THE VISIT , WORK-UP , EVALUATION OR STAGING AT TIME OF DX OR RECURRENCE	G9050	
FOCUS OF THE VISIT , TREATMENT DECISION-MAKING AFTER STAGING OR RE-STAGING, DISCUSSION OF TREATMENT OPTIONS, SUPERVISION OF CARE, MANAGEMENT OF CONSEQUENCES OF CARE	G9051	
FOCUS OF VISIT SURVEILLANCE FOR DISEASE RECURRENCE AFTER TREATMENT COMPLETION AND NO EVIDENCE OF DISEASE; FUTURE TREATMENT MAY BE CONSIDERED	G9052	
FOCUS OF VISIT , EXPECTANT MANAGEMENT OF PATIENT WITH EVIDENCE OF DISEASE WHO IS NOT IN TREATMENT; BUT FUTURE TREATMENT MAY BE CONSIDERED	G9053	
FOCUS OF VISIT , SUPERVISION OR MANAGEMENT OF PALLIATIVE CARE FOR TERMINAL DISEASE, END OF LIFE CARE, OR NO FURTHER CANCER TREATMENT INDICATED	G9054	
FOCUS OF VISIT NOT OTHERWISE LISTED OR SPECIFIED	G9055	
PATIENT MANAGEMENT ADHERES TO ASCO OR NCCN GUIDELINES. SPECIFY GUIDELINES BY CIRCLING NCCN ASCO BOTH	G9056	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES AS RESULT OF PATIENT ENROLLMENT IN IRB CLINICAL TRIAL; SPECIFY TRIAL IN CHART	G9057	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES BECAUSE PHYSICIAN DISAGREES WITH THEM	G9058	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES BECAUSE THE PATIENT REFUSED THEM AFTER BEING OFFERED GUIDELINES AND OPTED FOR OTHER TREATMENT	G9059	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES DUE TO A CO-MORBID CONDITION OR PERFORMANCE STATUS NOT FACTORED INTO GUIDELINE	G9060	
PATIENT CONDITION NOT ADDRESSED BY AVAILABLE GUIDELINES	G9061	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES FOR REASONS NOT ELSEWHERE SPECIFIED OR OTHER REASONS	G9062	
CANCERS AND STAGES--SEE LONG DESCRIPTIONS FOR CELL TYPES		
LUNG CANCER		
NSCLC, INITIALLY ESTABLISHED AS Stage I PRIOR TO NEO-ADJUVANT THERAPY Stable	G9063	
NSCLC, INITIALLY ESTABLISHED AS Stage II PRIOR TO NEO-ADJUVANT THERAPY, Stable	G9064	
NSCLC INITIALLY ESTABLISHED AS Stage IIIA PRIOR TO NEO-ADJUVANT THERAPY, Stable	G9065	
NSCLC, Stage IIIB-IV AT DIAGNOSIS, METS, LOCALLY RECURRENT or PROGRESSIVE	G9066	
NSCLC, Stage , Unknown or Not Specified	G9067	
SCLC or Combined NSCLC/SCLC Limited AT DIAGNOSIS	G9068	
SCLC or Combined NSCLC/SCLC AT DIAGNOSIS Extensive or CURRENT PROGRESSION, METS	G9069	
SCLC or Combined NSCLC/SCLC Unknown or Unspecified	G9070	

Physicians who use this form have read and comprehend the long descriptors of all codes herein and understand that they are primarily responsible for codes submitted.

Signature _____

PATIENT NAME:
 MR #:
 DATE OF SERVICE:

SHORT DESC	CODE	CHOICE
DIAGNOSIS INVASIVE FEMALE BREAST CANCER (Accepted Codes= 174.0-174.9)		
0= Nipple/aureola 1= Central 2 = Upper-inner Quadrant 3= Lower-inner Quadrant 4= Upper-outer Quadrant 5= Lower-outer Quadrant 6= Axillary Tail 8= Other Sites 9= Unlisted or Unspecified		
ESTABLISHED PATIENT, OFFICE VISIT, PROBLEM FOCUSED	99212	
ESTABLISHED PATIENT, EXPANDED PROBLEM FOCUSED	99213	
ESTABLISHED PATIENT, DETAILED	99214	
ESTABLISHED PATIENT. COMPREHENSIVE	99215	
FOCUS OF THE VISIT , WORK-UP , EVALUATION OR STAGING AT TIME OF DX OR RECURRENCE	G9050	
FOCUS OF THE VISIT , TREATMENT DECISION-MAKING AFTER STAGING OR RE-STAGING, DISCUSSION OF TREATMENT OPTIONS, SUPERVISION OF CARE, MANAGEMENT OF CONSEQUENCES OF CARE	G9051	
FOCUS OF VISIT SURVEILLANCE FOR DISEASE RECURRENCE AFTER TREATMENT COMPLETION AND NO EVIDENCE OF DISEASE; FUTURE TREATMENT MAY BE CONSIDERED	G9052	
FOCUS OF VISIT , EXPECTANT MANAGEMENT OF PATIENT WITH EVIDENCE OF DISEASE WHO IS NOT IN TREATMENT; BUT FUTURE TREATMENT MAY BE CONSIDERED	G9053	
FOCUS OF VISIT , SUPERVISION OR MANAGEMENT OF PALLIATIVE CARE FOR TERMINAL DISEASE, END OF LIFE CARE, OR NO FURTHER CANCER TREATMENT INDICATED	G9054	
FOCUS OF VISIT NOT OTHERWISE LISTED OR SPECIFIED	G9055	
PATIENT MANAGEMENT ADHERES TO ASCO OR NCCN GUIDELINES. SPECIFY GUIDELINES BY CIRCLING NCCN ASCO BOTH	G9056	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES AS RESULT OF PATIENT ENROLLMENT IN IRB CLINICAL TRIAL; SPECIFY TRIAL IN CHART	G9057	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES BECAUSE PHYSICIAN DISAGREES WITH THEM	G9058	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES BECAUSE THE PATIENT REFUSED THEM AFTER BEING OFFERED GUIDELINES AND OPTED FOR OTHER TREATMENT	G9059	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES DUE TO A CO-MORBID CONDITION OR PERFORMANCE STATUS NOT FACTORED INTO GUIDELINE	G9060	
PATIENT CONDITION NOT ADDRESSED BY AVAILABLE GUIDELINES	G9061	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES FOR REASONS NOT ELSEWHERE SPECIFIED OR OTHER REASONS	G9062	
CANCERS AND STAGES--SEE LONG DESCRIPTIONS FOR CELL TYPES		
FEMALE BREAST CANCER (NOT DCIS)		
INVASIVE BREAST CANCER STAGE I or IIA-IIB or T3, N1, M0, ER AND/OR PR positive, STABLE	G9071	
INVASIVE BREAST CANCER STAGE I or IIA-IIB or T3, N1, M0, ER AND NEGATIVE, STABLE	G9072	
INVASIVE BREAST CANCER STAGE IIIA-IIIIB NOT T3, N1, M0, ER AND/OR PR positive, STABLE	G9073	
INVASIVE BREAST CANCER STAGE IIIA-IIIIB NOT T3, N1, M0, ER/PR NEGATIVE, STABLE	G9074	
INVASIVE BREAST CANCER, M1 at DX, or LOCALLY RECURRENT OR PROGRESSION	G9075	
INVASIVE BREAST CANCER Unspecified or Unknown OR PRE-SURGICAL	G9076	

Physicians who use this form have read and comprehend the long descriptors of all codes herein and understand that they are primarily responsible for codes submitted.

Signature _____

PATIENT NAME:
 MR #:
 DATE OF SERVICE:

SHORT DESC	CODE	CHOICE
DIAGNOSIS PROSTATE CANCER (Accepted Code =185)		
185 = Malignant Cancer Prostate	185	
ESTABLISHED PATIENT, OFFICE VISIT, PROBLEM FOCUSED	99212	
ESTABLISHED PATIENT, EXPANDED PROBLEM FOCUSED	99213	
ESTABLISHED PATIENT, DETAILED	99214	
ESTABLISHED PATIENT. COMPREHENSIVE	99215	
FOCUS OF THE VISIT , WORK-UP , EVALUATION OR STAGING AT TIME OF DX OR RECURRENCE	G9050	
FOCUS OF THE VISIT , TREATMENT DECISION-MAKING AFTER STAGING OR RE-STAGING, DISCUSSION OF TREATMENT OPTIONS, SUPERVISION OF CARE, MANAGEMENT OF CONSEQUENCES OF CARE	G9051	
FOCUS OF VISIT SURVEILLANCE FOR DISEASE RECURRENCE AFTER TREATMENT COMPLETION AND NO EVIDENCE OF DISEASE; FUTURE TREATMENT MAY BE CONSIDERED	G9052	
FOCUS OF VISIT , EXPECTANT MANAGEMENT OF PATIENT WITH EVIDENCE OF DISEASE WHO IS NOT IN TREATMENT; BUT FUTURE TREATMENT MAY BE CONSIDERED	G9053	
FOCUS OF VISIT , SUPERVISION OR MANAGEMENT OF PALLIATIVE CARE FOR TERMINAL DISEASE, END OF LIFE CARE, OR NO FURTHER CANCER TREATMENT INDICATED	G9054	
FOCUS OF VISIT NOT OTHERWISE LISTED OR SPECIFIED	G9055	
PATIENT MANAGEMENT ADHERES TO ASCO OR NCCN GUIDELINES. SPECIFY GUIDELINES BY CIRCLING NCCN ASCO BOTH	G9056	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES AS RESULT OF PATIENT ENROLLMENT IN IRB CLINICAL TRIAL; SPECIFY TRIAL IN CHART	G9057	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES BECAUSE PHYSICIAN DISAGREES WITH THEM	G9058	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES BECAUSE THE PATIENT REFUSED THEM AFTER BEING OFFERED GUIDELINES AND OPTED FOR OTHER TREATMENT	G9059	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES DUE TO A CO-MORBID CONDITION OR PERFORMANCE STATUS NOT FACTORED INTO GUIDELINE	G9060	
PATIENT CONDITION NOT ADDRESSED BY AVAILABLE GUIDELINES	G9061	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES FOR REASONS NOT ELSEWHERE SPECIFIED OR OTHER REASONS	G9062	
CANCERS AND STAGES--SEE LONG DESCRIPTIONS FOR CELL TYPES		
PROSTATE CANCER (LIMITED TO ADENOCARCINOMA AS PREDOMINANT CELL TYPE)		
PROSTATE CANCER, T1-2C, GLEASON 2-7, PSA , < OR EQUAL TO 20 AT DX STABLE	G9077	
PROSTATE CANCER, T2 OR GLEASON 8-10 OR PSA > 20 AT DX, STABLE	G9078	
PROSTATE CANCER T3B-T4 ANY N, ANY T, N1 AT DX. STABLE	G9079	
PROSTATE CANCER, AT INITIAL TREATMENT RISING PSA OR LACK OF DECLINE	G9080	
PROSTATE CANCER, METS PROGRESSION OR M1 AT DIAGNOSIS, NO CASTRATE	G9081	
PROSTATE CANCER, METS PROGRESSION OR M1 AT DIAGNOSIS, CASTRATE	G9082	
PROSTATE CANCER, UNSPECIFIED OR UNKNOWN OR UNDER EVALUATION	G9083	

Physicians who use this form have read and comprehend the long descriptors of all codes herein and understand that they are primarily responsible for codes submitted.

Signature _____

PATIENT NAME:
 MR #:
 DATE OF SERVICE:

SHORT DESC	CODE	CHOICE
DIAGNOSIS COLON CANCER (Accepted Codes = 153.0-153.9)		
0=Hepatic flexure 1= Transverse 2= Descending 3= Sigmoid 4= Cecum 5= Appendix 6= Ascending 7= Splenic flexure 8= Other Site 9= Unspecified		
ESTABLISHED PATIENT, OFFICE VISIT, PROBLEM FOCUSED	99212	
ESTABLISHED PATIENT, EXPANDED PROBLEM FOCUSED	99213	
ESTABLISHED PATIENT, DETAILED	99214	
ESTABLISHED PATIENT, COMPREHENSIVE	99215	
FOCUS OF THE VISIT , WORK-UP , EVALUATION OR STAGING AT TIME OF DX OR RECURRENCE	G9050	
FOCUS OF THE VISIT , TREATMENT DECISION-MAKING AFTER STAGING OR RE-STAGING, DISCUSSION OF TREATMENT OPTIONS, SUPERVISION OF CARE, MANAGEMENT OF CONSEQUENCES OF CARE	G9051	
FOCUS OF VISIT SURVEILLANCE FOR DISEASE RECURRENCE AFTER TREATMENT COMPLETION AND NO EVIDENCE OF DISEASE; FUTURE TREATMENT MAY BE CONSIDERED	G9052	
FOCUS OF VISIT , EXPECTANT MANAGEMENT OF PATIENT WITH EVIDENCE OF DISEASE WHO IS NOT IN TREATMENT; BUT FUTURE TREATMENT MAY BE CONSIDERED	G9053	
FOCUS OF VISIT , SUPERVISION OR MANAGEMENT OF PALLIATIVE CARE FOR TERMINAL DISEASE, END OF LIFE CARE, OR NO FURTHER CANCER TREATMENT INDICATED	G9054	
FOCUS OF VISIT NOT OTHERWISE LISTED OR SPECIFIED	G9055	
PATIENT MANAGEMENT ADHERES TO ASCO OR NCCN GUIDELINES. SPECIFY GUIDELINES BY CIRCLING NCCN ASCO BOTH	G9056	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES AS RESULT OF PATIENT ENROLLMENT IN IRB CLINICAL TRIAL; SPECIFY TRIAL IN CHART	G9057	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES BECAUSE PHYSICIAN DISAGREES WITH THEM	G9058	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES BECAUSE THE PATIENT REFUSED THEM AFTER BEING OFFERED GUIDELINES AND OPTED FOR OTHER TREATMENT	G9059	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES DUE TO A CO-MORBID CONDITION OR PERFORMANCE STATUS NOT FACTORED INTO GUIDELINE	G9060	
PATIENT CONDITION NOT ADDRESSED BY AVAILABLE GUIDELINES	G9061	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES FOR REASONS NOT ELSEWHERE SPECIFIED OR OTHER REASONS	G9062	
CANCERS AND STAGES--SEE LONG DESCRIPTIONS FOR CELL TYPES		
COLON CANCER (ADENOCARCINOMA AS THE PREDOMINANT CELL TYPE)		
COLON CANCER, EXTENT OF DISEASE INITIALLY ESTABLISHED AS T1-3, N0, M0, STABLE	G9084	
COLON CANCER, EXTENT OF DISEASE INITIALLY ESTABLISHED AS T4, N0, M0, STABLE	G9085	
COLON CANCER, EXTENT OF DISEASE INITIALLY ESTABLISHED AS T1-4, N1-2, M0, STABLE	G9086	
COLON CANCER, M1 AT DX, METS OR RECURRENT WITH CURRENT CLINICAL, RADIOLOGICAL, OR BIOCHEMICAL EVIDENCE OF DISEASE	G9087	
COLON CANCER, M1 AT DX, METS OR RECURRENT WITH NO EVIDENCE OF DISEASE CURRENTLY	G9088	
COLON CANCER, UNSPECIFIED OR UNKNOWN	G9089	

Physicians who use this form have read and comprehend the long descriptors of all codes herein and understand that they are primarily responsible for codes submitted.

Signature _____

PATIENT NAME:
 MR #:
 DATE OF SERVICE:

SHORT DESC	CODE	CHOICE
DIAGNOSIS RECTAL CANCER (Accepted Codes= 154.0, 154.1)		
154.0 = Rectosigmoid junction 154.1 = Rectum		
ESTABLISHED PATIENT, OFFICE VISIT, PROBLEM FOCUSED	99212	
ESTABLISHED PATIENT, EXPANDED PROBLEM FOCUSED	99213	
ESTABLISHED PATIENT, DETAILED	99214	
ESTABLISHED PATIENT. COMPREHENSIVE	99215	
FOCUS OF THE VISIT , WORK-UP , EVALUATION OR STAGING AT TIME OF DX OR RECURRENCE	G9050	
FOCUS OF THE VISIT , TREATMENT DECISION-MAKING AFTER STAGING OR RE-STAGING, DISCUSSION OF TREATMENT OPTIONS, SUPERVISION OF CARE, MANAGEMENT OF CONSEQUENCES OF CARE	G9051	
FOCUS OF VISIT SURVEILLANCE FOR DISEASE RECURRENCE AFTER TREATMENT COMPLETION AND NO EVIDENCE OF DISEASE; FUTURE TREATMENT MAY BE CONSIDERED	G9052	
FOCUS OF VISIT , EXPECTANT MANAGEMENT OF PATIENT WITH EVIDENCE OF DISEASE WHO IS NOT IN TREATMENT; BUT FUTURE TREATMENT MAY BE CONSIDERED	G9053	
FOCUS OF VISIT , SUPERVISION OR MANAGEMENT OF PALLIATIVE CARE FOR TERMINAL DISEASE, END OF LIFE CARE, OR NO FURTHER CANCER TREATMENT INDICATED	G9054	
FOCUS OF VISIT NOT OTHERWISE LISTED OR SPECIFIED	G9055	
PATIENT MANAGEMENT ADHERES TO ASCO OR NCCN GUIDELINES. SPECIFY GUIDELINES BY CIRCLING NCCN ASCO BOTH	G9056	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES AS RESULT OF PATIENT ENROLLMENT IN IRB CLINICAL TRIAL; SPECIFY TRIAL IN CHART	G9057	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES BECAUSE PHYSICIAN DISAGREES WITH THEM	G9058	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES BECAUSE THE PATIENT REFUSED THEM AFTER BEING OFFERED GUIDELINES AND OPTED FOR OTHER TREATMENT	G9059	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES DUE TO A CO-MORBID CONDITION OR PERFORMANCE STATUS NOT FACTORED INTO GUIDELINE	G9060	
PATIENT CONDITION NOT ADDRESSED BY AVAILABLE GUIDELINES	G9061	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES FOR REASONS NOT ELSEWHERE SPECIFIED OR OTHER REASONS	G9062	
CANCERS AND STAGES--SEE LONG DESCRIPTIONS FOR CELL TYPES		
RECTAL CANCER (LIMITED TO INVASIVE ADENOCARCINOMA AS PREDOMINANT CELL TYPE)		
RECTAL CANCER, T1-2, N0, M0 PRIOR TO NEO-ADJUVANT THERAPY IF ANY, STABLE	G9090	
RECTAL CANCER, T3, N0, M0 PRIOR TO NEO-ADJUVANT THERAPY IF ANY, STABLE	G9091	
RECTAL CANCER, T1-3, N1-2 PRIOR TO NEO-ADJUVANT THERAPY IF ANY, M0, STABLE	G9092	
RECTAL CANCER, T4, ANY N, M0 PRIOR TO NEO-ADJUVANT THERAPY IF ANY, STABLE	G9093	
RECTAL CANCER M1 AT DX, METS OR RECURRENT OR PROGRESSION	G9094	
RECTAL CANCER, UNKNOWN, PRE-SURGICAL, OR UNSPECIFIED	G9095	

Physicians who use this form have read and comprehend the long descriptors of all codes herein and understand that they are primarily responsible for codes submitted.

Signature _____

PATIENT NAME:
 MR #:
 DATE OF SERVICE:

SHORT DESC	CODE	CHOICE
DIAGNOSIS ESOPHAGEAL CANCER (Accepted Codes = 150.0-150.9)		
0= Cervical 1= Thoracic 2= Abdominal 3= Upper Third 4= Middle Third 5= Lower Third 8= Other Part 9= Unspecified		
ESTABLISHED PATIENT, OFFICE VISIT, PROBLEM FOCUSED	99212	
ESTABLISHED PATIENT, EXPANDED PROBLEM FOCUSED	99213	
ESTABLISHED PATIENT, DETAILED	99214	
ESTABLISHED PATIENT. COMPREHENSIVE	99215	
FOCUS OF THE VISIT , WORK-UP , EVALUATION OR STAGING AT TIME OF DX OR RECURRENCE	G9050	
FOCUS OF THE VISIT , TREATMENT DECISION-MAKING AFTER STAGING OR RE-STAGING, DISCUSSION OF TREATMENT OPTIONS, SUPERVISION OF CARE, MANAGEMENT OF CONSEQUENCES OF CARE	G9051	
FOCUS OF VISIT SURVEILLANCE FOR DISEASE RECURRENCE AFTER TREATMENT COMPLETION AND NO EVIDENCE OF DISEASE; FUTURE TREATMENT MAY BE CONSIDERED	G9052	
FOCUS OF VISIT , EXPECTANT MANAGEMENT OF PATIENT WITH EVIDENCE OF DISEASE WHO IS NOT IN TREATMENT; BUT FUTURE TREATMENT MAY BE CONSIDERED	G9053	
FOCUS OF VISIT , SUPERVISION OR MANAGEMENT OF PALLIATIVE CARE FOR TERMINAL DISEASE, END OF LIFE CARE, OR NO FURTHER CANCER TREATMENT INDICATED	G9054	
FOCUS OF VISIT NOT OTHERWISE LISTED OR SPECIFIED	G9055	
PATIENT MANAGEMENT ADHERES TO ASCO OR NCCN GUIDELINES. SPECIFY GUIDELINES BY CIRCLING NCCN ASCO BOTH	G9056	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES AS RESULT OF PATIENT ENROLLMENT IN IRB CLINICAL TRIAL; SPECIFY TRIAL IN CHART	G9057	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES BECAUSE PHYSICIAN DISAGREES WITH THEM	G9058	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES BECAUSE THE PATIENT REFUSED THEM AFTER BEING OFFERED GUIDELINES AND OPTED FOR OTHER TREATMENT	G9059	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES DUE TO A CO-MORBID CONDITION OR PERFORMANCE STATUS NOT FACTORED INTO GUIDELINE	G9060	
PATIENT CONDITION NOT ADDRESSED BY AVAILABLE GUIDELINES	G9061	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES FOR REASONS NOT ELSEWHERE SPECIFIED OR OTHER REASONS	G9062	
CANCERS AND STAGES--SEE LONG DESCRIPTIONS FOR CELL TYPES		
ESOPHAGEAL CANCER (LIMITED TO ADENOCARCINOMA OR SQUAMOUS CELL)		
ESOPHAGEAL CANCER, EXTENT OF DISEASE INITIALLY ESTABLISHED AS T1-3, N0-1, OR NX PRIOR TO NEO-ADJUVANT THERAPY, IF ANY STABLE	G9096	
ESOPHAGEAL CANCER, INITIAL DX T4, ANY N, M0 PRIOR TO NEO-ADJUVANT THERAPY IF ANY, STABLE	G9097	
ESOPHAGEAL CANCER, M1 AT DX, METS, PROGRESSIVE OR LOCALLY RECURRENT	G9098	
ESOPHAGEAL CANCER, UNSPECIFIED OR UNKNOWN	G9099	

Physicians who use this form have read and comprehend the long descriptors of all codes herein and understand that they are primarily responsible for codes submitted.

Signature _____

PATIENT NAME:
 MR #:
 DATE OF SERVICE:

SHORT DESC	CODE	CHOICE
DIAGNOSIS GASTRIC CANCER (Accepted Codes 151.0-151.9)		
0= Cardia 1= Pylorus 2= Pyloric Antrum 3= Fundus 4= Body of stomach 5= Lesser curvature 6= Greater curvature 8= Other specified sites 9= Unspecified		
ESTABLISHED PATIENT, OFFICE VISIT, PROBLEM FOCUSED	99212	
ESTABLISHED PATIENT, EXPANDED PROBLEM FOCUSED	99213	
ESTABLISHED PATIENT, DETAILED	99214	
ESTABLISHED PATIENT, COMPREHENSIVE	99215	
FOCUS OF THE VISIT , WORK-UP , EVALUATION OR STAGING AT TIME OF DX OR RECURRENCE	G9050	
FOCUS OF THE VISIT , TREATMENT DECISION-MAKING AFTER STAGING OR RE-STAGING, DISCUSSION OF TREATMENT OPTIONS, SUPERVISION OF CARE, MANAGEMENT OF CONSEQUENCES OF CARE	G9051	
FOCUS OF VISIT SURVEILLANCE FOR DISEASE RECURRENCE AFTER TREATMENT COMPLETION AND NO EVIDENCE OF DISEASE; FUTURE TREATMENT MAY BE CONSIDERED	G9052	
FOCUS OF VISIT , EXPECTANT MANAGEMENT OF PATIENT WITH EVIDENCE OF DISEASE WHO IS NOT IN TREATMENT; BUT FUTURE TREATMENT MAY BE CONSIDERED	G9053	
FOCUS OF VISIT , SUPERVISION OR MANAGEMENT OF PALLIATIVE CARE FOR TERMINAL DISEASE, END OF LIFE CARE, OR NO FURTHER CANCER TREATMENT INDICATED	G9054	
FOCUS OF VISIT NOT OTHERWISE LISTED OR SPECIFIED	G9055	
PATIENT MANAGEMENT ADHERES TO ASCO OR NCCN GUIDELINES. SPECIFY GUIDELINES BY CIRCLING NCCN ASCO BOTH	G9056	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES AS RESULT OF PATIENT ENROLLMENT IN IRB CLINICAL TRIAL; SPECIFY TRIAL IN CHART	G9057	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES BECAUSE PHYSICIAN DISAGREES WITH THEM	G9058	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES BECAUSE THE PATIENT REFUSED THEM AFTER BEING OFFERED GUIDELINES AND OPTED FOR OTHER TREATMENT	G9059	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES DUE TO A CO-MORBID CONDITION OR PERFORMANCE STATUS NOT FACTORED INTO GUIDELINE	G9060	
PATIENT CONDITION NOT ADDRESSED BY AVAILABLE GUIDELINES	G9061	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES FOR REASONS NOT ELSEWHERE SPECIFIED OR OTHER REASONS	G9062	
CANCERS AND STAGES--SEE LONG DESCRIPTIONS FOR CELL TYPES		
GASTRIC CANCER (LIMITED TO ADENOCARCINOMA AS THE PREDOMINANT CELL TYPE)		
GASTRIC CANCER, POST R0 RESECTION, STABLE	G9100	
GASTRIC CANCER, POST R1-2, RESECTION, STABLE	G9101	
GASTRIC CANCER, M0, UNRESECTABLE, STABLE	G9102	
GASTRIC CANCER, M1 AT DX, METS, OR RECURRENT	G9103	
GASTRIC CANCER, UNDER EVALUATION, PRE-SURGICAL, UNKNOWN OR UNSPECIFIED	G9104	

Physicians who use this form have read and comprehend the long descriptors of all codes herein and understand that they are primarily responsible for codes submitted.

Signature _____

PATIENT NAME:
 MR #:
 DATE OF SERVICE:

SHORT DESC	CODE	CHOICE
DIAGNOSIS PANCREATIC CANCER (Accepted Codes= 157.0, 157.1, 157.2, 157.3, 157.8,157.9)		
0= Head of Pancreas 1= Body of Pancreas 2= Tail 3= Duct 8= Other specified sites 9= Unspecified		
ESTABLISHED PATIENT, OFFICE VISIT, PROBLEM FOCUSED	99212	
ESTABLISHED PATIENT, EXPANDED PROBLEM FOCUSED	99213	
ESTABLISHED PATIENT, DETAILED	99214	
ESTABLISHED PATIENT. COMPREHENSIVE	99215	
FOCUS OF THE VISIT , WORK-UP , EVALUATION OR STAGING AT TIME OF DX OR RECURRENCE	G9050	
FOCUS OF THE VISIT , TREATMENT DECISION-MAKING AFTER STAGING OR RE-STAGING, DISCUSSION OF TREATMENT OPTIONS, SUPERVISION OF CARE, MANAGEMENT OF CONSEQUENCES OF CARE	G9051	
FOCUS OF VISIT SURVEILLANCE FOR DISEASE RECURRENCE AFTER TREATMENT COMPLETION AND NO EVIDENCE OF DISEASE; FUTURE TREATMENT MAY BE CONSIDERED	G9052	
FOCUS OF VISIT , EXPECTANT MANAGEMENT OF PATIENT WITH EVIDENCE OF DISEASE WHO IS NOT IN TREATMENT; BUT FUTURE TREATMENT MAY BE CONSIDERED	G9053	
FOCUS OF VISIT , SUPERVISION OR MANAGEMENT OF PALLIATIVE CARE FOR TERMINAL DISEASE, END OF LIFE CARE, OR NO FURTHER CANCER TREATMENT INDICATED	G9054	
FOCUS OF VISIT NOT OTHERWISE LISTED OR SPECIFIED	G9055	
PATIENT MANAGEMENT ADHERES TO ASCO OR NCCN GUIDELINES. SPECIFY GUIDELINES BY CIRCLING NCCN ASCO BOTH	G9056	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES AS RESULT OF PATIENT ENROLLMENT IN IRB CLINICAL TRIAL; SPECIFY TRIAL IN CHART	G9057	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES BECAUSE PHYSICIAN DISAGREES WITH THEM	G9058	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES BECAUSE THE PATIENT REFUSED THEM AFTER BEING OFFERED GUIDELINES AND OPTED FOR OTHER TREATMENT	G9059	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES DUE TO A CO-MORBID CONDITION OR PERFORMANCE STATUS NOT FACTORED INTO GUIDELINE	G9060	
PATIENT CONDITION NOT ADDRESSED BY AVAILABLE GUIDELINES	G9061	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES FOR REASONS NOT ELSEWHERE SPECIFIED OR OTHER REASONS	G9062	
CANCERS AND STAGES--SEE LONG DESCRIPTIONS FOR CELL TYPES		
PANCREATIC CANCER (LIMITED TO ADENOCARCINOMA AS THE PREDOMINANT CELL TYPE)		
PANCREATIC CANCER, POST R0, RESECTION, STABLE	G9105	
PANCREATIC CANCER, POST R1 OR R2 RESECTION, STABLE	G9106	
PANCREATIC CANCER UNRESECTABLE OR M1 AT DX, METS, PROGRESSION OR RECURRENT	G9107	
PANCREATIC CANCER, UNSPECIFIED OR UNKNOWN	G9108	

Physicians who use this form have read and comprehend the long descriptors of all codes herein and understand that they are primarily responsible for codes submitted.

Signature_____

PATIENT NAME:
 MR #:
 DATE OF SERVICE:

SHORT DESC	CODE	CHOICE
DIAGNOSIS HEAD AND NECK CANCER (Accepted Codes = 140.0-149.9, 161.0-161.9)		
TOO MANY CODES TO LIST		
ESTABLISHED PATIENT, OFFICE VISIT, PROBLEM FOCUSED	99212	
ESTABLISHED PATIENT, EXPANDED PROBLEM FOCUSED	99213	
ESTABLISHED PATIENT, DETAILED	99214	
ESTABLISHED PATIENT. COMPREHENSIVE	99215	
FOCUS OF THE VISIT , WORK-UP , EVALUATION OR STAGING AT TIME OF DX OR RECURRENCE	G9050	
FOCUS OF THE VISIT , TREATMENT DECISION-MAKING AFTER STAGING OR RE-STAGING, DISCUSSION OF TREATMENT OPTIONS, SUPERVISION OF CARE, MANAGEMENT OF CONSEQUENCES OF CARE	G9051	
FOCUS OF VISIT SURVEILLANCE FOR DISEASE RECURRENCE AFTER TREATMENT COMPLETION AND NO EVIDENCE OF DISEASE; FUTURE TREATMENT MAY BE CONSIDERED	G9052	
FOCUS OF VISIT , EXPECTANT MANAGEMENT OF PATIENT WITH EVIDENCE OF DISEASE WHO IS NOT IN TREATMENT; BUT FUTURE TREATMENT MAY BE CONSIDERED	G9053	
FOCUS OF VISIT , SUPERVISION OR MANAGEMENT OF PALLIATIVE CARE FOR TERMINAL DISEASE, END OF LIFE CARE, OR NO FURTHER CANCER TREATMENT INDICATED	G9054	
FOCUS OF VISIT NOT OTHERWISE LISTED OR SPECIFIED	G9055	
PATIENT MANAGEMENT ADHERES TO ASCO OR NCCN GUIDELINES. SPECIFY GUIDELINES BY CIRCLING NCCN ASCO BOTH	G9056	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES AS RESULT OF PATIENT ENROLLMENT IN IRB CLINICAL TRIAL; SPECIFY TRIAL IN CHART	G9057	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES BECAUSE PHYSICIAN DISAGREES WITH THEM	G9058	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES BECAUSE THE PATIENT REFUSED THEM AFTER BEING OFFERED GUIDELINES AND OPTED FOR OTHER TREATMENT	G9059	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES DUE TO A CO-MORBID CONDITION OR PERFORMANCE STATUS NOT FACTORED INTO GUIDELINE	G9060	
PATIENT CONDITION NOT ADDRESSED BY AVAILABLE GUIDELINES	G9061	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES FOR REASONS NOT ELSEWHERE SPECIFIED OR OTHER REASONS	G9062	
HEAD AND NECK CANCER (LIMITED TO CANCERS OF THE ORAL CAVITY, PHARYNX, AND LARYNX)		
HEAD AND NECK CANCER, INITIALLY ESTABLISHED AS T1-2, N0, MO PRIOR TO NEO-ADJUVANT THERAPY IF ANY, STABLE	G9109	
HEAD AND NECK CANCER, INITIALLY ESTABLISHED AS T3-4 AND/OR N1-3, MO PRIOR TO NEO-ADJUVANT THERAPY IF ANY, STABLE	G9110	
HEAD AND NECK CANCER, M1 AT DX, PROGRESSION, OR RECURRENT	G9111	
HEAD AND NECK CANCER, UNKNOWN OR UNSPECIFIED	G9112	

Physicians who use this form have read and comprehend the long descriptors of all codes herein and understand that they are primarily responsible for codes submitted.

Signature _____

PATIENT NAME:
 MR #:
 DATE OF SERVICE:

SHORT DESC	CODE	CHOICE
DIAGNOSIS OVARIAN CANCER (Accepted Codes = 183.0)		
183.0 = Malignant Cancer of the ovary	183.0	
ESTABLISHED PATIENT, OFFICE VISIT, PROBLEM FOCUSED	99212	
ESTABLISHED PATIENT, EXPANDED PROBLEM FOCUSED	99213	
ESTABLISHED PATIENT, DETAILED	99214	
ESTABLISHED PATIENT. COMPREHENSIVE	99215	
FOCUS OF THE VISIT , WORK-UP , EVALUATION OR STAGING AT TIME OF DX OR RECURRENCE	G9050	
FOCUS OF THE VISIT , TREATMENT DECISION-MAKING AFTER STAGING OR RE-STAGING, DISCUSSION OF TREATMENT OPTIONS, SUPERVISION OF CARE, MANAGEMENT OF CONSEQUENCES OF CARE	G9051	
FOCUS OF VISIT SURVEILLANCE FOR DISEASE RECURRENCE AFTER TREATMENT COMPLETION AND NO EVIDENCE OF DISEASE; FUTURE TREATMENT MAY BE CONSIDERED	G9052	
FOCUS OF VISIT , EXPECTANT MANAGEMENT OF PATIENT WITH EVIDENCE OF DISEASE WHO IS NOT IN TREATMENT; BUT FUTURE TREATMENT MAY BE CONSIDERED	G9053	
FOCUS OF VISIT , SUPERVISION OR MANAGEMENT OF PALLIATIVE CARE FOR TERMINAL DISEASE, END OF LIFE CARE, OR NO FURTHER CANCER TREATMENT INDICATED	G9054	
FOCUS OF VISIT NOT OTHERWISE LISTED OR SPECIFIED	G9055	
PATIENT MANAGEMENT ADHERES TO ASCO OR NCCN GUIDELINES. SPECIFY GUIDELINES BY CIRCLING NCCN ASCO BOTH	G9056	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES AS RESULT OF PATIENT ENROLLMENT IN IRB CLINICAL TRIAL; SPECIFY TRIAL IN CHART	G9057	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES BECAUSE PHYSICIAN DISAGREES WITH THEM	G9058	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES BECAUSE THE PATIENT REFUSED THEM AFTER BEING OFFERED GUIDELINES AND OPTED FOR OTHER TREATMENT	G9059	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES DUE TO A CO-MORBID CONDITION OR PERFORMANCE STATUS NOT FACTORED INTO GUIDELINE	G9060	
PATIENT CONDITION NOT ADDRESSED BY AVAILABLE GUIDELINES	G9061	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES FOR REASONS NOT ELSEWHERE SPECIFIED OR OTHER REASONS	G9062	
CANCERS AND STAGES--SEE LONG DESCRIPTIONS FOR CELL TYPES		
OVARIAN CANCER, LIMITED TO EPITHELIAL CANCER		
OVARIAN CANCER, PATHOLOGICAL STAGE I A-B, GRADE 1, STABLE	G9113	
OVARIAN CANCER, PATHOLOGICAL STAGE I A -B GRADE 2-3 OR STAGE 1C OR STAGE II, STABLE	G9114	
OVARIAN CANCER STAGE III-IV, STABLE	G9115	
OVARIAN CANCER, PROGRESSION, RECURRENCE OR PLATINUM RESISTANCE	G9116	
OVARIAN CANCER, UNKNOWN OR UNSPECIFIED	G9117	

Physicians who use this form have read and comprehend the long descriptors of all codes herein and understand that they are primarily responsible for codes submitted.

Signature _____

PATIENT NAME:
 MR #:
 DATE OF SERVICE:

SHORT DESC	CODE	CHOICE
DIAGNOSIS NON-HODGKIN'S LYMPHOMA (NHL) (Accepted Codes= 202.00-202.08, 202.80-202.98)		
202.0x = Nodular lymphoma; 202.8x = Other lymphomas; 202.9x = Other and unspecified cancer of the lymphoid and histiocytic tissue; x is fifth digits as follows--0=Unspecified site, extranodal, solid organ 1= nodes of the face, head, and neck 2= intrathoracic nodes 3= intra-abdominal nodes 4= axilla, upper limb nodes 5 = inguinal, lower limb nodes 6= intrapelvic nodes 7= spleen 8= multiple sites		
ESTABLISHED PATIENT, OFFICE VISIT, PROBLEM FOCUSED	99212	
ESTABLISHED PATIENT, EXPANDED PROBLEM FOCUSED	99213	
ESTABLISHED PATIENT, DETAILED	99214	
ESTABLISHED PATIENT. COMPREHENSIVE	99215	
FOCUS OF THE VISIT , WORK-UP , EVALUATION OR STAGING AT TIME OF DX OR RECURRENCE	G9050	
FOCUS OF THE VISIT , TREATMENT DECISION-MAKING AFTER STAGING OR RE-STAGING, DISCUSSION OF TREATMENT OPTIONS, SUPERVISION OF CARE, MANAGEMENT OF CONSEQUENCES OF CARE	G9051	
FOCUS OF VISIT SURVEILLANCE FOR DISEASE RECURRENCE AFTER TREATMENT COMPLETION AND NO EVIDENCE OF DISEASE; FUTURE TREATMENT MAY BE CONSIDERED	G9052	
FOCUS OF VISIT , EXPECTANT MANAGEMENT OF PATIENT WITH EVIDENCE OF DISEASE WHO IS NOT IN TREATMENT; BUT FUTURE TREATMENT MAY BE CONSIDERED	G9053	
FOCUS OF VISIT , SUPERVISION OR MANAGEMENT OF PALLIATIVE CARE FOR TERMINAL DISEASE, END OF LIFE CARE, OR NO FURTHER CANCER TREATMENT INDICATED	G9054	
FOCUS OF VISIT NOT OTHERWISE LISTED OR SPECIFIED	G9055	
PATIENT MANAGEMENT ADHERES TO ASCO OR NCCN GUIDELINES. SPECIFY GUIDELINES BY CIRCLING NCCN ASCO BOTH	G9056	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES AS RESULT OF PATIENT ENROLLMENT IN IRB CLINICAL TRIAL; SPECIFY TRIAL IN CHART	G9057	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES BECAUSE PHYSICIAN DISAGREES WITH THEM	G9058	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES BECAUSE THE PATIENT REFUSED THEM AFTER BEING OFFERED GUIDELINES AND OPTED FOR OTHER TREATMENT	G9059	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES DUE TO A CO-MORBID CONDITION OR PERFORMANCE STATUS NOT FACTORED INTO GUIDELINE	G9060	
PATIENT CONDITION NOT ADDRESSED BY AVAILABLE GUIDELINES	G9061	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES FOR REASONS NOT ELSEWHERE SPECIFIED OR OTHER REASONS	G9062	
CANCERS AND STAGES--SEE LONG DESCRIPTIONS FOR CELL TYPES		
NON-HODGKIN'S LYMPHOMA (NHL) LIMITED TO FOLLICULAR LYPHOMA, MANTLE CELL, DIFFUSE B-CELL, SMALL LYMPHOCYTIC LYMPHOMA		
NHL, STAGE I-II AT DX, NOT RELAPSED, NOT REFRACTORY	G9118	
NHL, STAGE III-IV AT DX, NOT RELAPSED, NOT REFRACTORY	G9119	
NHL, TRANSFORMED TO DIFFUSE LARGE B-CELL LYMPHOMA	G9120	
NHL, RELAPSED AND REFRACTORY	G9121	
NHL, STAGE UNDER EVALUATION, UNKNOWN OR UNSPECIFIED	G9122	

Physicians who use this form have read and comprehend the long descriptors of all codes herein and understand that they are primarily responsible for codes submitted.

Signature _____

PATIENT NAME:
 MR #:
 DATE OF SERVICE:

SHORT DESC	CODE	CHOICE
DIAGNOSIS CHRONIC MYELOGENOUS LEUKEMIA (Accepted Codes = 205.10 and 205.11)		
205.10 = Chronic Myeloid leukemia, without mention of remission 205.11= Chronic Myeloid Leukemia in remission		
ESTABLISHED PATIENT, OFFICE VISIT, PROBLEM FOCUSED	99212	
ESTABLISHED PATIENT, EXPANDED PROBLEM FOCUSED	99213	
ESTABLISHED PATIENT, DETAILED	99214	
ESTABLISHED PATIENT. COMPREHENSIVE	99215	
FOCUS OF THE VISIT , WORK-UP , EVALUATION OR STAGING AT TIME OF DX OR RECURRENCE	G9050	
FOCUS OF THE VISIT , TREATMENT DECISION-MAKING AFTER STAGING OR RE-STAGING, DISCUSSION OF TREATMENT OPTIONS, SUPERVISION OF CARE, MANAGEMENT OF CONSEQUENCES OF CARE	G9051	
FOCUS OF VISIT SURVEILLANCE FOR DISEASE RECURRENCE AFTER TREATMENT COMPLETION AND NO EVIDENCE OF DISEASE; FUTURE TREATMENT MAY BE CONSIDERED	G9052	
FOCUS OF VISIT , EXPECTANT MANAGEMENT OF PATIENT WITH EVIDENCE OF DISEASE WHO IS NOT IN TREATMENT; BUT FUTURE TREATMENT MAY BE CONSIDERED	G9053	
FOCUS OF VISIT , SUPERVISION OR MANAGEMENT OF PALLIATIVE CARE FOR TERMINAL DISEASE, END OF LIFE CARE, OR NO FURTHER CANCER TREATMENT INDICATED	G9054	
FOCUS OF VISIT NOT OTHERWISE LISTED OR SPECIFIED	G9055	
PATIENT MANAGEMENT ADHERES TO ASCO OR NCCN GUIDELINES. SPECIFY GUIDELINES BY CIRCLING NCCN ASCO BOTH	G9056	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES AS RESULT OF PATIENT ENROLLMENT IN IRB CLINICAL TRIAL; SPECIFY TRIAL IN CHART	G9057	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES BECAUSE PHYSICIAN DISAGREES WITH THEM	G9058	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES BECAUSE THE PATIENT REFUSED THEM AFTER BEING OFFERED GUIDELINES AND OPTED FOR OTHER TREATMENT	G9059	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES DUE TO A CO-MORBID CONDITION OR PERFORMANCE STATUS NOT FACTORED INTO GUIDELINE	G9060	
PATIENT CONDITION NOT ADDRESSED BY AVAILABLE GUIDELINES	G9061	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES FOR REASONS NOT ELSEWHERE SPECIFIED OR OTHER REASONS	G9062	
CANCERS AND STAGES--SEE LONG DESCRIPTIONS FOR CELL TYPES		
CHRONIC MYELOGENOUS LEUKEMIA, PHILADELPHIA CHRMOSOME POSITIVE AND/OR BCR-ABL POSITIVE		
CML, PHIL CHROMO + AND/OR BCR-ABL + CHRONIC PHASE, NOT IN REMISSION	G9123	
CML, PHIL CHROMO + AND/OR BCR-ABL + ACCELERATED, NOT IN REMISSION	G9124	
CML, BLAST PHASE NOT IN REMISSION	G9125	
CML, PHIL CHROMO + AND/OR BCR-ABL +, IN REMISSION	G9126	
CML, STAGE UNKNOWN OR UNSPECIFIED	G9127	

Physicians who use this form have read and comprehend the long descriptors of all codes herein and understand that they are primarily responsible for codes submitted.

Signature _____

PATIENT NAME:
 MR #:
 DATE OF SERVICE:

SHORT DESC	CODE	CHOICE
DIAGNOSIS MULTIPLE MYELOMA (Accepted Codes 203.00 and 203.01)		
203.00 = Multiple Myeloma, without mention of remission 203.01= Multiple Myeloma in remission		
ESTABLISHED PATIENT, OFFICE VISIT, PROBLEM FOCUSED	99212	
ESTABLISHED PATIENT, EXPANDED PROBLEM FOCUSED	99213	
ESTABLISHED PATIENT, DETAILED	99214	
ESTABLISHED PATIENT. COMPREHENSIVE	99215	
FOCUS OF THE VISIT , WORK-UP , EVALUATION OR STAGING AT TIME OF DX OR RECURRENCE	G9050	
FOCUS OF THE VISIT , TREATMENT DECISION-MAKING AFTER STAGING OR RE-STAGING, DISCUSSION OF TREATMENT OPTIONS, SUPERVISION OF CARE, MANAGEMENT OF CONSEQUENCES OF CARE	G9051	
FOCUS OF VISIT SURVEILLANCE FOR DISEASE RECURRENCE AFTER TREATMENT COMPLETION AND NO EVIDENCE OF DISEASE; FUTURE TREATMENT MAY BE CONSIDERED	G9052	
FOCUS OF VISIT , EXPECTANT MANAGEMENT OF PATIENT WITH EVIDENCE OF DISEASE WHO IS NOT IN TREATMENT; BUT FUTURE TREATMENT MAY BE CONSIDERED	G9053	
FOCUS OF VISIT , SUPERVISION OR MANAGEMENT OF PALLIATIVE CARE FOR TERMINAL DISEASE, END OF LIFE CARE, OR NO FURTHER CANCER TREATMENT INDICATED	G9054	
FOCUS OF VISIT NOT OTHERWISE LISTED OR SPECIFIED	G9055	
PATIENT MANAGEMENT ADHERES TO ASCO OR NCCN GUIDELINES. SPECIFY GUIDELINES BY CIRCLING NCCN ASCO BOTH	G9056	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES AS RESULT OF PATIENT ENROLLMENT IN IRB CLINICAL TRIAL; SPECIFY TRIAL IN CHART	G9057	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES BECAUSE PHYSICIAN DISAGREES WITH THEM	G9058	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES BECAUSE THE PATIENT REFUSED THEM AFTER BEING OFFERED GUIDELINES AND OPTED FOR OTHER TREATMENT	G9059	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES DUE TO A CO-MORBID CONDITION OR PERFORMANCE STATUS NOT FACTORED INTO GUIDELINE	G9060	
PATIENT CONDITION NOT ADDRESSED BY AVAILABLE GUIDELINES	G9061	
PATIENT MANAGEMENT DIFFERS FROM GUIDELINES FOR REASONS NOT ELSEWHERE SPECIFIED OR OTHER REASONS	G9062	
CANCERS AND STAGES--SEE LONG DESCRIPTIONS FOR CELL TYPES		
MULTIPLE MYELOMA, SYSTEMIC DISEASE		
MULTIPLE MYELOMA, SMOLDERING STAGE 1	G9128	
MULTIPLE MYELOMA, STAGE II OR HIGHER	G9129	
MULTIPLE MYELOMA, STAGE UNKNOWN, UNDER EVALUATION, OR UNLISTED	G9130	

Physicians who use this form have read and comprehend the long descriptors of all codes herein and understand that they are primarily responsible for codes submitted.

Signature _____